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Ultrasound sensitive (sonosensitive liposomes) are drug delivery systems designed 
for releasing their drug load upon exposure to ultrasound (US). Inclusion of 
dioleoylphosphatidylethanolamine (DOPE) in liposome membranes was previously shown to 
induce sonosensitivity. For efficient US mediated drug delivery to solid tumours, a long blood 
circulation time of the liposomal drug providing high tumour uptake is required. In this study, 
blood pharmacokinetics of DOPE-based liposomal doxorubicin (DXR) were evaluated in 
mice. A markedly faster blood clearance of DXR was observed for DOPE-rich liposomes 
compared to Caelyx! (standard liposomal DXR). Subsequently, liposome membrane 
composition was altered to improve drug retention in the bloodstream, while maintaining 
sonosensitivity. Formulations with reduced blood clearance of DXR were obtained by 
reducing the content of DOPE from 62 to 32 or 25 mol%. These formulations showed long 
blood circulation time, as approximately 20% of the administered DXR dose was present in 
the bloodstream 24 h after intravenous injection. The reduction in liposomal DOPE content 
did not significantly reduce US mediated DXR release in vitro, indicating that DOPE is a 
potent modulator to sonosensitivity. The novel liposome formulations, containing moderate 
amounts of DOPE, displayed similar blood pharmacokinetic profiles as standard liposomal 
DXR, but a markedly improved sonosensitivity.  
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Liposomes that exhibit controlled release properties have potential for delivery of 
chemotherapeutic drugs to solid tumours. Ideally, liposomes should accumulate intact at the 
tumour site, and subsequently release their drug load. The extent of liposome accumulation in 
the tumour is largely determined by the blood circulation time of the liposomal drug, where 
liposomes that retain their drug over several hours to days will provide greater tumour 
delivery and less non-specific toxicity. For reviews see Drummond et al., 1999; Gabizon et 
al., 2003. After liposome accumulation within the tumour tissue, the encapsulated drug must 
be released before it can be taken up by the neoplastic cells (Horowitz et al., 1992). In the 
case of long circulating PEGylated doxorubicin (DXR)-liposomes, the drug has shown to leak 
slowly from the liposome (Horowitz et al., 1992; Colbern et al., 2000). Thus, triggered 
destabilization of the liposome carrier within the tumour area might lead to a substantial 
increase in drug availability and thus improved therapeutic efficacy.  
Recently, there has been increasing interest in using ultrasound (US) as a means to 
physically and non-invasively trigger drug release from liposomes upon accumulation in 
tumour tissue (de Smet et al., 2010; Schroeder et al., 2009; Myhr and Moan, 2006; Pong et 
al., 2006). Local application of US to tumours produces several effects, such as enhancing 
extravasation of liposomes to tumours, inducing drug leakage from the liposome carrier and 
enhancing cell membrane permeability with a resulting increased intracellular drug uptake 
(For recent reviews see Schroeder et al., 2009; Pitt et al., 2004; Frenkel, 2008). In order to 
maximize the therapeutic efficacy, liposomes should display properties that both impart high 
US sensitivity (sonosensitivity) and favour drug retention in the blood stream, to enable 
sufficient tumour accumulation. Several studies have shown that gas-containing particles are 
highly sonosensitive (Huang et al., 2008; Unger et al., 1998; Huang and MacDonald., 2004). 
Unfortunately, gas-filled liposomes are micron-sized and thus too large to allow for effective 
extravasation into tumour tissue (Ferrara, 2008; Maeda et al., 2000). Another limitation of 
such particles is the rapid dissolution of the entrapped gas in blood circulation with 
consequent loss of sonosensitivity (Unger et al., 1998; Ferrara, 2008).  
An approach to formulate gas-free liposomes combining high sonosensitivity with 
long blood circulations times might be to modulate the liposome membrane composition. 
Previously, we demonstrated that PEGylated liposomes comprising 
phosphatidylethanolamine showed a several fold increase in drug release compared to 
Caelyx! (standard liposomal DXR) during in vitro exposure to US (Evjen et al., 2010; Evjen 
et al., 2011a; Evjen et al., 2011b). An US enhanced therapeutic activity of DSPE-based 
liposomal DXR was demonstrated in tumoured mice (Hagtvet et al., 2010). Recently, we 
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found that liposomes based on DOPE as the main phospholipid constituent displayed 
markedly improved sonosensitivity than DSPE-based liposomes (Evjen et al., 2011a). These 
DOPE-based liposomes, however, were not evaluated and optimized as drug carriers for in 
vivo applications.   
In the present study, blood circulation time of various DXR-containing liposome 
formulations combining DOPE with distearoylphosphatidylcholine (DSPC), PEGylated 
distearoylphosphatidylethanolamine (DSPE-PEG 2000) and cholesterol, were investigated in 
non-tumoured mice. Novel formulations combining high sonosensitivity and long blood 
residence time of DXR were obtained.  
 
2. MATERIALS AND METHODS  
 
2.1 Materials 
Cholesterol, HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid) 
ammonium sulfate, TritonX-100! solution and sucrose were obtained from Sigma Aldrich, 
Oslo, Norway. Serum of fetal bovine origin (Autonorm) was obtained from Sero (Billingstad, 
Norway). DSPE-PEG 2000) DSPC, DOPE, were purchased from Genzyme Pharmaceuticals, 
Liestal, Switzerland. Doxorubicin hydrochloride (DXR) was purchased from Nycomed, 
Asker, Norway. DXR-containing liposomes, Caelyx! (herein defined as standard liposomal 
DXR), comprising hydrogenated soy phosphatidylcholine (HSPC), DSPE-PEG 2000 and 
cholesterol (57:5:38 mol %) was supplied from the pharmacy at the Norwegian Radium 
Hospital, Oslo, Norway (European distributor Schering-Plough).  
 For anaesthesia of mice a mixture of 2.4 mg/ml tiletamine and 2.4 mg/ml zolazepam 
(Zoletil® vet, Virbac Laboratories, Carros, France), 3.8 mg/ml xylazine (Narcoxyl® vet, 
Roche, Basel, Switzerland) and 0.1 mg/ml butorphanol (Torbugesic®, Fort Dodge 
Laboratories, Fort Dodge, IA) was prepared and used.  
 
2.2 Liposome preparation 
Liposomes with different mol % of the lipids DOPE, DSPC, DSPE-PEG and 
cholesterol were prepared by the thin film hydration and sequential extrusion method 
similarly as previously described (Evjen et al., 2011a). (See Table 1, Section 3.2 for liposome 
membrane compositions). Briefly, dry lipid films were hydrated with 300 mM ammonium 
sulfate solution and exposed to three freeze/thaw cycles in a dry-ice/aceton/methanol mixture 
and water, respectively. The liposomes were reduced in size by stepwise extrusion (Lipex 
extruder, Biomembrane Inc., Vancouver B.C., Canada) through Nucleopore polycarbonate 
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filters with pore sizes of 800, 400, 200,100 and 80 nm (Nuclepore, West Chester, PA, USA). 
The mean target size of the liposomes was 85 ± 5 nm. 
DXR was remote loaded into liposomes using an ammonium sulfate transmembrane 
gradient (Haran et al., 1993), as previously described by Evjen et al., 2011a. The resulting 
nominal lipid and DXR concentrations were 16 mg/ml and 1 mg/ml, respectively.  
 
2.3 Liposome characterization 
The mean intensity-weighted hydrodynamic liposome diameter was determined by 
Photon Correlation Spectroscopy (Nanosizer, Malvern Instruments, Malvern, UK). The 
liposome dispersions were diluted prior to measurements in a ratio of 1:200 (v/v) with  0.22- 
µm- filtered sucrose/HEPES solution.  The measurements were performed at 23 ºC and at a 
scattering angle of 90°. The polydispersity index (P.I) was given as an indicator for the width 
of the particle size distribution. Triplicate measurements of each liposome batch were 
performed.   
 Determination of liposomal entrapment efficiency of DXR  was estimated by 
fluorescence measurements as previously described (Evjen et al., 2011). All liposome 
formulations displayed entrapment efficiencies of DXR of more than 95% (drug:lipid ratio 
1:16 wt/wt). 
 
2.4 Ultrasound mediated drug release 
US release measurements were conducted using a 40 kHz US transducer (VC 750, 
Sonic and Materials, Inc, Newtown, CT, USA) with a 19 mm diameter nonfocused probe 
mounted in a custom-built sample chamber as previously described (Evjen et al., 2010). In 
brief, the liposome dispersions were diluted in a 1:500 (v/v) ratio with sucrose/HEPES 
solution containing 20% serum, just prior to the US experiments. The diluted liposome 
dispersions were exposed to 40 kHz US at a nominal intensity of 12 W/cm2 in a continuous 
mode (100 % duty cycle) up to 6 min. Acoustic pressure measurements conducted with a 
Bruel and Kjaer hydrophone (Type 8103, Denmark) in the sample chamber gave 240 kPa 
(pk–pk). The temperature in the liposome samples never exceeded 30 °C during the US 
experiments, excluding the possibility of direct thermal effect of US on liposomal drug 
release.  
DXR release could be monitored due to the relief of DXR-mediated fluorescence 
self-quenching in the external liposomal phase, and concomitant increase in fluorescence 
intensity.  An optical fiber probe (Ocean optics, type QP600-2-VIS/BX, Florida, USA) was 
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used to measure in line the increase in  fluorescence intensity as a result of DXR release, 
using the following equation:  
 
Equation 1:  % Drug release = (Ft – F0)/ (Fmax-F0)*100 
 
Where F0 and Ft are the fluorescence intensities of a given liposome sample prior to and after 
a given duration (t) of US respectively, and Fmax is the fluorescence intensity after liposome 
solubilisation with surfactant (Triton-X 100). The diluted liposome samples were solubilised 
with Triton-X 100 at a ratio of 100:1 (v/v). Fluorescence intensity measurements were 
performed using a fluorescence spectrometer from Ocean Optics (model QE65000. Duiven, 
Netherlands). The excitation and emission wavelength for DXR were 488 and 595 nm, 
respectively. Triplicate samples were measured. 
 
2.5 Serum stability assay 
Liposome stability in vitro was studied using a well-established serum-induced 
leakage assay as previously described by Evjen et al., 2010. Liposome dispersions, diluted 
1:125 (v/v) with sucrose/HEPES solution containing 20% serum were incubated up to 24 h at 
37 ºC. Time-dependent leakage of DXR was quantified by fluorescence measurements, by 
further diluting the samples 1:4 (v/v) with sucrose/HEPES solution, according to Equation 1.  
Triplicate samples were measured. 
 
2.6 Pharmacokinetic and biodistribution studies in non-tumoured mice 
Male atymic nude Balb/c mice were provided by the Department of Comparative 
Medicine (animal facility), the Norwegian Radium Hospital. The mice were housed in 
transparent boxes with bedding material, fed ad libitum and kept under specific pathogen-free 
conditions. The temperature and relative humidity were kept constant at 20-21°C and 60%, 
respectively. At the end of the experiments all animals were euthanized by cervical 
dislocation. All procedures were performed according to protocols approved by the National 
Animal Research Authority and carried out in compliance with the European Convention for 
the Protection of Vertebrates Used for Scientific Purposes. 
The administered DXR dose for animals receiving the various DOPE-based 
liposomes was 7 mg/kg body weight. The DXR dose for animals receiving standard liposomal 
DXR was 14 mg/kg. The doubled DXR dose administered was due to the doubled drug-to 
lipid-ratio of the standard liposomes  (1:8 drug/lipid) versus DOPE-based liposomes  (1:16 
drug/lipid). Thus, the dosing was based on an identical lipid dose for all investigated liposome 
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formulations, as the lipid dose (i.e. liposome dose) is generally known as a key factor 
influencing blood pharmacokinetics (Drummond et al., 1999).  
The liposomes were injected intravenously (i.v.) into the tail vein under anaesthesia 
induced by subcutaneous administration of 0.1 ml anaesthetic agent. Animals were sacrificed 
in groups of three at different time points post injection (0.5, 1, 3, 8 12, 24, 48 h). Blood 
samples were obtained by cardiac puncture using heparinized syringes and stored in 
heparinized tubes. Liver, spleen and kidneys were excised and their weight registered. All 
blood and tissue samples were kept on ice bath until storage at -80 °C.  
Quantification of DXR was performed similarly as described by Gabizon et al., 1989. 
In brief, 0.1 ml of whole blood samples (lysed due to freezing) was mixed with 1.9 ml 
acidified ethanol (0.3 M HCl in 50% ethanol) giving a final 1:20 (v/v) dilution. Duplicate 
samples were prepared for further processing. Tissue samples were added 50% acidified 
ethanol in a final 1:10 (v/v) dilution and homogenized using a Homogenizer PRO 200! 
(PRO Scientific, Monroe, CT, USA). The digested blood and tissue samples were incubated 
for 24 h at 4 °C in the dark. Following incubation the precipitate was removed by 
centrifugation (20000 g, 20 min, 4 °C) and the supernatant (containing extracted DXR) stored 
at -20°C until fluorescence measurements were performed. The extracted DXR was 
quantified by fluorescence measurements as previously described using multipoint standard 
curves. The latter were generated by adding known amounts of standard liposomal DXR to 
blood and tissue (liver, spleen and kidney) homogenate and incubated and centrifuged as 
described above. All calibration curves had regression coefficients (R2)>0,99. 
 
2.7 Statistics 
 All data are reported as mean values with standard deviation. Statistical comparison 
of the DXR concentration in blood and organs for the different liposome formulations was 
performed at each time point post injection using a student t-test with p<0.05. 
 
3. RESULTS 
3.1 Blood pharmacokinetics of prototype DOPE-based liposomes 
DOPE-based liposomes with membrane composition DOPE:DSPC:DSPE-PEG 
2000:CHOL 62:10:8:20 mol%  were previously demonstrated to release their DXR load 
almost completely during 4 minutes of  US exposure in vitro (Evjen et al., 2011). 
Furthermore these liposomes showed negligible leakage of DXR during 24 h in vitro 
incubation in sucrose/HEPES solution containing 20% serum at 37 °C  (Evjen et al., 2011). 
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Hence, this DOPE-based formulation was first selected for assessment of blood 
pharmacokinetics in mice. Blood levels of DXR provide a good indication of liposomal drug 
retention, since DXR released in the bloodstream is rapidly distributed to other tissues and 
organs (Gabizon et al., 1989). 
Fig 1 shows the blood clearance profiles of DXR for DOPE-based liposomes in 
comparison to standard liposomal DXR. Both formulations showed exponential declines in 
blood concentrations, starting with a rapid decline in DXR blood concentrations followed by 
a slower elimination phase. In the first distribution phase, DXR concentrations were 
comparable between the two formulations. In the slower elimination phase, starting 
approximately at 3 h post injection, a significantly lower blood concentration was observed 
for the DOPE-based liposomes as compared to standard liposomal DXR. At 24 h post 
injection only 5% of the injected DXR dose remained in blood for the DOPE-based liposomes 
versus 20% for standard liposomal DXR (Fig 1). 
 
 
Fig 1. Blood clearance kinetics of i.v. injected liposomal DXR in mice, ! DOPE-based 
liposomes (DOPE:DSPC:DSPE-PEG 2000:Chol; 62:10:8:20 mol%) in comparison to ! 
standard liposomal DXR (HSPC:DSPE-PEG 2000:Chol; 57:5:38 mol%). Bars represent the 




3.2 Effect of lipid composition on DXR blood pharmacokinetics of DOPE-based liposomes 
Further, both blood clearance kinetics and in vitro sonosensitivity for a range of 
DOPE-based formulations with different lipid composition were investigated. Unsaturated 
phospholipids, like DOPE, fluidize the liposome membrane thereby increasing the membrane 
permeability at physiological temperature due to their low gel-to-liquid-crystalline phase 
transition temperature (Tc)  (Demel et al., 1976). Previous studies have shown that addition of 
cholesterol to liposomes rigidifies the bilayer and reduces leakage of entrapped material at 
temperatures above the Tc of the membrane (Gregoriadis, 1988; Damen et al., 1981; Ishida et 
al., 2006).  
In an attempt to prolong blood circulation time of DOPE-containing liposomal DXR, 
membrane composition was altered by both increasing the level of cholesterol and reducing 
the level of DOPE. An overview of the different formulations produced is presented in Table 
1.  
Note that all formulations were comparable in terms of mean size and drug-to-lipid 
ratio, and differed only in membrane composition. The comparable liposome size was 
essential to better assess the influence of the membrane composition per se on blood 
circulation time and biodistribution. In vitro leakage studies showed no detectable leakage of 
DXR from the liposomes during the course of 24 h incubation in 20% serum at 37 ºC.  
 
Table 1. Overview of DXR-containing DOPE-liposomes.  
 
At a constant DOPE level of 52 mol% no change in blood clearance were observed 
for liposomes containing different cholesterol levels up to 40 mol% (formulation no 1-4) (Fig 
2). In contrast, liposomal DXR containing an intermediate level of DOPE (32 and 25 mol%, 
respectively), and consequently an increased level of DSPC (20 and 27 mol%, respectively), 






% DXR in 
plasma 
24 h post inj. 
% DXR 
released 
6 min post US 
1 
62:10:8.20 
86 (0.14) 5 ±  1 91±  2 
2 52:5:8:35 86 (0.12) 3 ± 1 79 ± 1 
3 52:20:8:20 80 (0.10) 4  ± 1 78 ± 6 
4 52:0:8:40 86 (0.10) 2 ± 0 74 ± 1 
5 32:20:8.40 86 (0.10) 20 ± 3 87 ± 2 
6 25:27:8:40 87 (0.10) 17 ± 1 71 ± 4 
7 12:40:8:40 83 (0.10) NA 11 ± 1 
8 Standard liposomal DXR 76 (0.11) 21 ± 1 3 ± 1 
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for these intermediate DOPE formulations were approximately similar to standard liposomal 
DXR, where about 20% of the injected DXR dose remained in blood circulation 24 h after 
injection (Fig 3). 
 
Fig 2. Blood clearance kinetics of i.v. injected liposomal DXR in mice of liposomes 
containing the following cholesterol levels; ! 20 mol%, " 35 mol%, ! 40 mol%. (DOPE 
and DSPE-PEG 2000 levels: 52 and 8 mol%, respectively. DSPC level co varies with 
cholesterol level). ! standard liposomal DXR (HSPC:DSPE-PEG 2000:Chol; 57:5:38 mol%) 




Fig 3. Blood clearance kinetics of i.v. injected liposomal DXR in mice of liposomes 
containing the following DOPE levels; ! 25 mol% and "32 mol%. (Cholesterol and DSPE-
PEG 2000 levels: 40 and 8 mol%, respectively. DSPC level co varies with DOPE level). # 
standard liposomal DXR (HSPC:DSPE-PEG 2000:Chol; 57:5:38 mol%) is included for 
comparison. Bars represent the SD of the mean (n=3).  
 
3.3 Effect of lipid composition on biodistribution of DOPE-containing liposomal DXR 
If the relatively faster blood clearance of DXR for DOPE-rich liposomes was a 
consequence of carrier recognition by the mononuclear phagocyte system (MPS), then a 
corresponding increased accumulation in liver and spleen would be expected. Hence, DXR 
levels in liver, spleen and kidneys were investigated for two formulations comprising 32 and 
52 mol% DOPE, respectively (no 4 and 5). These two formulations, herein termed 
intermediatelevel and highlevel DOPE-containing liposomes, showed a relatively slow and 
fast blood clearance of DXR, respectively (Fig 2 and 3). 
No significant differences in DXR concentration in spleen could be observed for the 
intermediate and highlevel DOPE formulations (Fig 4B). The data revealed a slightly lower 
DXR concentration in liver for the highlevel DOPE-containing liposomes (Fig 4A). However, 
the difference was only significant at 12 h and 48 h post injection, p<0.05 (Fig 4A). Thus, the 
faster blood clearance profile of DXR for this formulation most likely reflected leakage of 
DXR from the liposome carrier, and not an increased uptake by the MPS. 
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Moreover, for the highlevel DOPE-containing liposomes, DXR levels in kidneys 
reached a maximum 12 h after injection. The intermediatelevel DOPE-containing liposomes 
showed sustained levels of DXR throughout the course of the experiment (Fig 4C). This 
pattern may reflect slow release of DXR from the intermediatelevel DOPE-containing 
liposomes in blood circulation, as indicated in Figs 2 and 3, resulting in higher DXR 











Fig 4. % DXR of injected dose in (A) liver, (B) spleen and (C) kidneys after i.v. injection of 
DOPE:DSPC:DSPE-PEG 2000:Cholesterol liposomes in mice: ! 52:0:8:40 mol%, 
!32:20:8:40 mol%. Bars represent SD of the mean (n=3).  
 
3.4 Effect of DOPE level on sonosensitivity  
Variations in lipid membrane composition are shown to influence sonosensitivity of 
liposomes (Pong et al., 2006; Schroeder et al., 2009; Evjen et al., 2010a; Evjen et al., 2010b; 
Lin et al., 2001). We recently demonstrated that incorporation of DOPE into liposome 
bilayers drastically enhanced sonosensitivity compared to DSPE-based liposomes and 
standard liposomal DXR, respectively (Evjen et al., 2011a). The minimum amount of DOPE 
required for maintaining an acceptable sonosensitivity in vitro, however, was not explored.  
Fig 5 compares the US mediated DXR release profiles of liposomes containing 
different amounts of DOPE, during exposure to 40 kHz US in sucrose/HEPES solution 
containing 20% serum. High sonosensitivity was observed for formulations comprising 
between 25 and 52 mol% DOPE (Fig 5). These formulations showed up to a 7-fold increase 
in DXR release extent when compared to standard liposomal DXR after 6 min US exposure. 
Poor sonosensitivity was observed for liposomes composed of 12 mol% DOPE, as evidenced 
by a significant reduction in DXR release (Fig 5).  
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Fig 5. Effect of DOPE level on US mediated DXR release from liposomes in HEPES/sucrose 
solution containing 20% serum (40 kHz US). DOPE-levels: ! 32 mol%, " 52 mol%, # 25 
mol%, ! 12 mol%. (Cholesterol and DSPE-PEG 2000 levels: 40 and 8 mol%, respectively. 
DSPC level co varies). $ standard liposomal DXR (HSPC:DSPE-PEG 2000:Chol; 57:5:38 




Application of sonosensitive liposomes for US mediated drug delivery requires that 
the liposomes retain their drug contents in blood circulation until they reach the tumour 
tissue. The results of the current study showed that DOPE-containing liposomes combining 
long blood circulation time of DXR with sufficient sonosensitivity might be obtained by 
altering liposome membrane composition.  
 The results demonstrated that lipid composition significantly influenced the blood 
clearance kinetics of DOPE-based liposomal DXR. The in vivo blood clearance of liposomal 
drug is mainly determined by two factors: (1) uptake of intact liposomes by the MPS, (2) 
leakage of the entrapped drug from the liposomes in blood circulation. In general, small 
PEGylated liposomes below 100 nm in diameter, as described in the current study, are to a 
certain extent able to escape the MPS, which in turn provides prolonged blood circulation 
time of the liposome carrier and consequently increased accumulation within tumour tissue. 
For reviews see Drummond et al., 1999; Gabizon et al., 2003. For successful drug delivery, it 
is required that the liposomes are able to retain the entrapped drug in blood circulation en 
route to the tumour tissue.  
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 The liposomes comprising high levels of DOPE (62 and 52 mol%) showed relatively 
faster blood clearance of DXR than standard liposomal DXR (Fig 1). This finding may reflect 
leakage of DXR from the liposome carrier due to high membrane permeability and 
consequent distribution to other tissues, and/or premature uptake of the DOPE-rich liposomes 
by the MPS. The DOPE-based liposomes showed no in vitro DXR leakage in 20% serum. 
However, the stability in vitro may not always reflect liposomal drug retention in vivo, due to 
e.g. differences in the composition of bovine serum and mice blood. Discrepancy between in 
vitro and in vivo leakage results has previously been observed  (Charrois and Allen., 2004; 
Mayer et al., 1990).   
Previous studies have demonstrated faster blood clearance kinetics of liposomal drugs 
composed of fluid lipids as a consequence of drug leakage (Charrois et al., 2004, Gabizon et 
al., 1988; Gabizon et al., 1993., Ishida et al., 2006). The permeability of liposome bilayers is 
to a great extent modulated by the Tc of the phospholipids and the presence of cholesterol 
(Gabizon et al., 2003). DOPE has a Tc of -16 °C (Cullis et al., 1978), resulting in highly fluid 
membranes at physiological temperature that are more permeable to molecules and ions. A 
partial loss of transmembrane ion-gradient might account for an elevated percentage of non-
ionized DXR in the liposome interior and subsequently DXR leakage.  
Furthermore, a correlation between liposome permeability, lipid phase transition and 
cholesterol content has been established previously (Papahadjopoulos, 1996; Demel et al., 
1976). In general, cholesterol is known to improve the physical stability of PC-based 
liposomes by tightening the lipid membrane, reducing its permeability and consequently 
leakage of entrapped drug (Demel et al., 1976). It was therefore interesting to note that no 
prolonged blood circulation time was obtained by increasing the cholesterol level from 20 to 
40 mol% in DOPE-rich liposomes. The lack of any cholesterol stabilizing effect might be 
related to membrane packing constrains such as inhomogeneous distribution of cholesterol 
within the lipid membranes and/or poor cholesterol-phospholipid interactions, leading to high 
membrane permeability (Demel et al., 1976). 
When the DOPE level in liposomes was reduced to 32 mol% or below, the amount of 
DSPC in the membrane was consequently increased. The significantly prolonged blood 
circulation time of DXR for these formulations was probably both a result of reduced levels 
of DOPE and increased levels of DSPC. Previous studies have shown that saturated 
phosphatidylcholine provides order and rigidity to fluid-like lipid membranes and prolongs 
the blood residence time of liposomal drugs due to reduced leakage from the carrier (Demel 
et al., 1976; Charrois et al., 2004; Gabizon et al., 1988; Ishida et al., 2006; Senior et al., 
1982).  
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The biodistribution studies indicates that the faster blood clearance for the DOPE-rich 
liposomal DXR was not the result of enhanced uptake by the MPS but due to increased 
leakage of DXR from the liposome carrier. This could be assumed as no increased uptake of 
DXR in liver and spleen was observed for the DOPE-rich liposomes, which displayed the 
lowest blood concentrations. On the contrary, slightly higher levels of DXR in liver and 
predominantly in kidneys were observed for the long circulating intermediatelevel DOPE-
containing liposomes. Considering slower release of DXR from the intermediatelevel DOPE-
containing liposomes in blood circulation, increased delivery of the liposome-encapsulated 
DXR to tissues would be expected. The significantly higher DXR concentrations in the 
kidneys at the latest time points after injection might reflect a sustained release of DXR in 
blood circulation. It should not be excluded, though, that the different blood clearance of 
liposomes comprising intermediate and high levels of DOPE also could be explained by 
different extent of uptake or accumulation in other organs or tissues not investigated here, 
such as the skin or paws.  
There is a well-established correlation between long blood circulation time and 
increased liposome accumulation in tumours (Gill et al., 1995). Hence, the prolonged blood 
circulation time for the 25 and 32 mol% DOPE-containing liposomes should provide a good 
basis for efficient tumour accumulation. To enable full availability of DXR to tumour cells, 
the DOPE-containing liposomes should be sufficiently destabilized by US at the tumour site. 
Interestingly, the in vitro sonosensitivity of liposomes was largely maintained down to a level 
of 25 mol% DOPE. This particular formulation, comprising DOPE:DSPC:DSPE-
PEG:cholesterol 25:27:8:40 mol%, showed approximately 70% release of DXR after 6 min 
US exposure in 20% serum. The results suggest that DOPE is a very potent sonosensitivity 
modulator, as only small amounts of the lipid were required to achieve efficient US mediated 
drug release. The DOPE-liposomes represented a several fold improvement in sonosensitivity 
compared to DSPE-based liposomal DXR and standard liposomal DXR, respectively 
(Hagtvet et al., 2010; Evjen et al., 2011).  
The US regime used in the current study (4 min 40 kHz US) is recently reported to 
induce a significant tumour regression in mice receiving DSPE-based liposomes, without 
inducing any acute toxicity (Hagtvet et al., 2010). However, for further preclinical and 
clinical studies of DOPE-containing liposomes a more sophisticated US device enabling 
increased focusing ability to tumours may be preferred. This will be accomplished by using 
high frequency focused US probes. However, previous studies have shown that 
sonosensitivity of the liposomes are comparable using 40 kHz and 1.13 MHz US (Evjen et 
al., 2011b).  
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In conclusion, novel sonosensitive and long-circulating DXR-liposomes containing 
DOPE were developed by optimising the membrane composition. Low or moderate amounts 
of DOPE were required to obtain a sufficiently long blood circulation time after i.v. injection 
in mice. This reduction in DOPE level did not adversely affect sonosensitivity. Further 
studies are required to establish whether the novel formulations in combination with US 
improve DXR delivery to tumour cells enhancing the therapeutic index.  
 
ACKNOWLEDGEMENTS 
The project is supported by an industrial PhD grant from the Norwegian Research Council. 
The authors thank Deneke Fetene (Dept of Radiation Biology, Institute for Cancer Research, 
Oslo University Hospital), Sibylla Røgnvaldsson and Robert A. Fowler (Epitarget AS, Oslo), 




Charrois, G.J.R., Allen, T.M., 2004. Drug release rate influences the pharmacokinetics, 
biodistribution, therapeutic activity, and toxicity of PEGylated liposomal doxorubicin 
formulations in murine breast cancer. Biochim Biophysic Acta.  1663,167-177. 
 
Colbern, G., Vaage, J., Donovan, D., Uster, P., Working, P., 2000. Tumor uptake and 
therapeutic effects of drugs encapsulated in long-circulating PEGylated stealth liposomes. 
Journal of liposome research.  10, 81-92. 
 
Cullis, P.R., Akshay, lagna P.R., de kruijff, B., 1978., The polymorphic phase behaviour of 
phosphatidylethanolamines of natural and synthetic origin. A 31P NMR study. Biochim 
Biophys Acta.  513, 31-42. 
 
Damen, J., Regts, J., Scherphof, G., 1981. Transfer and exchange of phospholipid between 
small unilamellar liposomes and rat plasma high density lipoproteins. Dependence on 
cholesterol content and phospholipid composition. Biochim Biophys Acta.  665, 538-545. 
 
Demel, R.A., De kruyff, B., 1976. The function of sterols in membranes. Biochim Biophys 
Acta.  457, 109-132. 
 
de Smet, M., Heijman, E., Langereis, S., Hijnen, N., Grull, H., 2010. Mangnetic resonance 
imaging of high intensity focused ultrasound mediated drug delivery from temperature-
sensitive liposomes: An in vivo proof-of-concept study. Journal of Controlled Release. In 
press. 
 
Drummond, D.C., Meyer, O., Hong, K., Kirpotin, D.B., Papahadjopoulos, D., 1999. 
Optimizing liposomes for delivery of chemotherapeutic agents to solid tumours. 
Pharmacological Reviews.  51, 691-743. 
 
Evjen, T.J., Nilssen, E.A., Røgnvaldsson, S., Brandl, M., Fossheim, S.L., 2010. 
Distearoylphosphatidylethanolamine-based liposomes for ultrasound-mediated drug delivery. 
European Journal of Pharmaceutics and Biopharmaceutics.  75, 327-333. 
 
! "#!
Evjen, T.J., Nilssen, E.A., Barnert, S., Schubert, R., Brandl, M., Fossheim, S.L., 2011a. 
Ultrasound-mediated destabilization and drug release from liposomes comprising 
dioleoylphosphatidylethanolamine. European Journal of Pharmaceutical Sciences. 42, 380-
386. 
 
Evjen, T.J., Nilssen, E.A., Fowler, R.A, Røgnvaldsson, S., Brandl, M., Fossheim, S.L., 2011b. 
Lipid membrane composition influences drug release from 
dioleoylphosphatidylethanolamine-based liposomes on exposure to ultrasound. International 
Journal of Pharmaceutics. 406, 114-116. 
 
Ferrara, K., 2008. Driving delivery vehicles with ultrasound. Adv Drug Deliv Rev.  60, 1097-
1102. 
 
Frenkel, V., 2008. Ultrasound mediated delivery of drugs and genes to solid tumors. Adv 
Drug Deliv Rev. 60, 1193-1208. 
 
Gabizon, A., Papahadjopoulos, D., 1988. Liposome formulations with prolonged circulation 
time in blood and enhanced uptake by tumours. Proceedings of the National Academy of 
Sciences of the United States of America.  85, 6949-6953. 
 
Gabizon, A., Shiota, R., Papahadjopoulos, D., 1989. Pharmacokinetics and tissue distribution 
of doxorubicin encapsulated in stable liposomes with long circulation times. J Natl Cancer 
Inst.  81, 1484-1488. 
 
Gabizon, A., Barenholz, Y., Bialer, M., 1993. Prolongation of the circulation time of 
doxorubicin encapsulated in liposomes containing a polyethylene glycol-derivatized 
phospholipid: pharmakokinetic studies in rodents and dogs. Pharmaceutical Research. 10, 
703-708. 
 
Gabizon, A., Scmeeda, H., Barenholz, Y., 2003. Pharmacokinetics of PEGylated liposomal 
doxorubicin. Review of animal and human studies. Clin Pharmacokinet. 42, 419-436. 
 
Gill, P.S., Espina, B.M., Muggia, F., Cabriales, S., Tulpule, A., Esplin, J.A., Liebman, H.A., 
Forssen, E., Ross, M.E., Levine, A.M., 1995. Phase I/II clinical and pharmacokinetic 
evaluation of liposomal daunorubicin. J Clin Oncol.  13, 996-1003. 
 
Gregoriadis, G., 1988. Fate of injected liposomes: observations on entrapped solute retention, 
vesicle clearance and tissue distribution in vivo.  Liposomes as drug carriers, ed., Chichester: 
John Wiley & sons Ltd. p 3-18. 
 
Hagtvet, E., Evjen, T.J., Olsen, D.R., Fossheim, S., Nilssen, E.A., 2010. Ultrasound 
enhanched antitumour activity of liposomal doxorubicin in mice. Journal of drug targeting. In 
press. 
 
Haran, G., Cohen, R., Bar, L.K., Barenholz, Y., 1993. Transmembrane ammonium sulfate 
gradients in liposomes produce efficient and stable entrapment of amphipathic weak bases. 
Biochim Biophys Acta. 1151, 201-215. 
 
Horowitz, A.T., Barenholz, Y., Gabizon, A.A., 1992. In vitro cytotoxicity of liposome-
encapsulated doxorubicin: dependence on liposome composition and drug release. Biochim 
Biophys Acta.  1109, 203-209. 
 
Huang, S.-L., MacDonald, R.C., 2004. Acoustically active liposomes for drug encapsulation 
and ultrasound-triggered release. Biochim Biophys Acta,  1665, 134-141. 
  
! "#!
Huang, S.-L., McPherson, D.D., MacDonald, R.C., 2008. A method to co-encapsulate gas and 
drugs in liposomes for ultrasound-controlled drug delivery. Ultrasound in medicine and 
biology, 34, 1272-1280. 
  
Ishida, T., Okada, Y., Kobayashi, T., Kiwada, H., 2006. Development of pH-sensitive 
liposomes that efficiently retain encapsulated doxorubicin (DXR) in blood. International 
Journal of Pharmaceutics.  309, 94-100. 
 
Lin, H.,-Y., Thomas, J.L., 2004. Factors affecting responsitivity of unilamellar liposomes to 
20 kHz ultrasound. Langmuir.  20, 6100-6106. 
 
Maeda, H., Wu, J., Sawa, T., Matsumura, Y., Hori, K., 2000. Tumor vascular permeability 
and the EPR effect in macromolecular therapeutics: a review. J Controlled release.  65, 271-
284. 
 
Mayer, L.D., Bally, M.D., Loughrey, H., Masin, D., Cullis, P.R., 1990. Liposomal vincristine 
preparations which exhibit decreased drug toxicity and increased activity against murine L 
1210 and P388 tumors. Cancer research.  50, 575-579. 
 
Myhr, G., Moan, J., 2006. Synergistic and tumour selective effects of chemotherapy and 
ultrasound treatment. Cancer letters.  232, 206-213. 
 
Papahadjopoulos, D., 1996. Fate of liposomes in vivo: A brief introductory review. Journal of 
liposome research.  1, 3-17. 
 
Pitt, W.G., Husseini, G.A., Staples, B.J., 2004. Ultrasonic Drug Delivery- A General Review. 
Expert Opin Drug Deliv.  1, 37-56. 
 
Pong, M., Umchid, S., Guarino, A.J., Lewin, P.A., Litniewski, J., Nowichi, A., Wrenn, S.P., 
2006. In vitro ultrasound- mediated leakage from phospholipid vesicles. Ultrasonics.  45, 133-
145. 
 
Schroeder, A., Kost, J., Barenholz, Y., 2009. Ultrasound, liposomes, and drug delivery: 
principles for using ultrasound to control the release of drugs from liposomes. Chemistry and 
Physics of Lipids.  162, 1-16. 
 
Senior, J., Gregoriadis, G., 1982. Stability of small unilamellar liposomes in serum and 
clearance from the circulation: The effect of the phospholipid and cholesterol components. 
Life sciences.  30, 2123-2136. 
 
Unger, E.C., McCreery, T.P., Sweitzer, R.H., Caldwell, V.E., 1998. Acoustically active 
lipospheres containing paclitaxel: A new therapeutic ultrasound contrast agent. Investigative 
radiology.  33, 887-892. 
  
 
 
 
